GGSK重新进入印度癌症市场,使用两种新药物Jemperli和Zejula,旨在治疗内脏癌和卵巢癌。 GSK re-enters India's cancer market with two new drugs, Jemperli and Zejula, aimed at endometrial and ovarian cancers.

GlaxoSmithKline(GSK)与Jemperli和Zejula一起重新进入印度的癌症药物市场,治疗内脏癌和卵巢癌。 GlaxoSmithKline (GSK) re-enters India's cancer drug market with Jemperli and Zejula, treating endometrial and ovarian cancers. Jemperli是第一个针对晚期子宫颈癌的PD-1免疫疗法,而Zejula是PARP对晚期卵巢癌的唯一抑制剂。 Available at tiered pricing, Jemperli is the first PD-1 immunotherapy for advanced endometrial cancer, while Zejula is the only PARP inhibitor for advanced ovarian cancer. GSK还启动了一项病人支助方案,以改善获得这些疗法的机会。 GSK also launches a patient support program to improve access to these therapies.